Antisense technology: A review.

Area of Science:

• Biotechnology
• Molecular Biology
• Pharmacology

Background:

• Antisense technology has matured, with ten RNA-targeted drugs (eight single-strand antisense drugs (ASOs) and two double-strand ASOs (siRNAs)) now approved.
• ASOs in clinical trials exhibit innovation in delivery methods and target a spectrum of rare and common diseases, including cardiovascular conditions.

Purpose of the Study:

• To review the molecular mechanisms underlying the efficacy of antisense technology.
• To exemplify specific molecular mechanisms and challenges using recent clinical results of various ASOs.
• To provide a prospective outlook on the future of antisense technology.

Main Methods:

• Focus on molecular events driving observed effects of antisense drugs.
• Analysis of recent clinical trial data involving multiple ASOs.
• Literature review of advancements and applications in antisense technology.

Main Results:

• Ten RNA-targeted drugs, including ASOs and siRNAs, are commercially available.
• ASOs are being investigated in large-scale cardiovascular outcome studies and other significant clinical trials.
• Innovative delivery routes and diverse disease targets characterize current ASO development.

Conclusions:

• Antisense technology is demonstrating significant clinical success and therapeutic potential.
• Understanding molecular mechanisms is crucial for optimizing ASO therapies.
• The field is poised for continued growth and broader application in medicine.